Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00249808
Status:
COMPLETED
Last Update Posted:
2018-03-20
First Post:
2005-11-04
Brief Title:
A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed Have a Contraindication to or Are Intolerant of Other Systemic Therapies
Sponsor:
Organization:
Merck KGaA Darmstadt Germany